Close Menu

NEW YORK (360Dx) – Illumina said this week that the US Food and Drug Administration has granted breakthrough device designation for its pan-cancer assay, which is currently in development. Illumina plans to market the assay as TruSight Oncology Comprehensive. It will be based on the content of the firm's TruSight Oncology 500 (TSO 500) assay, which is designed to detect known and emerging biomarkers for solid tumors.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.